|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, MO, USA
2 Dalton Cardiovascular Research Center, University of Missouri-Columbia, Columbia, MO, USA
3 Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, MO, USA; Dalton Cardiovascular Research Center, University of Missouri-Columbia, Columbia, MO, USA
* To whom correspondence should be addressed. E-mail: milanickm{at}missouri.edu.
Chloro(2,2':6',2"-terpyridine) platinum, a bulky, hydrophilic reagent, inhibited the renal sodium pump with a single exponential time course. K+ increased the rate constant of the reaction by about 2 fold; the K+ concentration dependence was monotonic, with a half maximal effect observed at 1 mM, consistent with K+ acting at a transport site. Na+, Mg++, eosin, and vanadate did not significantly alter the rate of reaction. The results of proteolysis and mass spectrometer analysis were consistent with terpyridine platinum labeling of Cys452, 456 or 457. Since phenylarsine oxide reacts with vicinal cysteines and did not prevent terpyridine platinum modification, terpyridine platinum most likely modifies Cys452. This modification prevents ADP binding; interestingly, the analogous residue in SERCA is on the exterior of the nucleotide binding pocket. Thus, it appears that the terpyridine platinum residue is more accessible in the presence of K+ than in its absence and that terpyridine platinum modification prevents nucleotide binding.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |